News Hub | News Direct

Lifestyle

Beverage: Coffee/Tea/Non-Alcoholic Beverage: Spirits/Beer/Wine Casino/Gaming Fashion Food/Cooking/Baking Health & Fitness Home Goods Hospitality Leisure Activities & Hobbies Parenting Pets Photography Seniors Travel & Tourism
Article thumbnail News Release

ChillWell Launches ChillWell 2.0 Portable Air Cooler for Personal Space Chilling Benefits

Cosmic Wave

FOR IMMEDIATE RELEASE Contact: ChillWell Phone: 888-998-6324 Email: chillwell@rephelpdesk.com CHILLWELL LAUNCHES CHILLWELL 2.0 PORTABLE COOLER WITH INSTA-FROST TECHNOLOGY AT 55% DISCOUNT FOR A COMFORTABLE, COOL SUMMER New portable cooler decreases indoor air temperatures in minutes while helping save hundreds on utility and cooling bills FAIRFIELD, New Jersey – May 24, 2023 – Portable cooler company ChillWell has launched ChillWell 2.0, a new and improved version of its flagship product. Made with advanced Insta-Frost technology, ChillWell 2.0 can keep homes cool and comfortable all summer long. Insta-Frost uses the proven power of evaporative cooling to reduce the temperature of the air while adding moisture, helping homes stay cool, comfortable, and hydrated. ChillWell is promoting the new portable air cooler through a special 50% off promotion. For a limited time, you can buy ChillWell 2.0 for just $89.99 per unit. “ChillWell 2.0 is our most advanced portable cooler yet,” explains a company spokesperson. “Our team developed Insta-Frost to rapidly cool indoor air temperatures in small and medium-sized spaces, and it works as advertised to help anyone stay cool and comfortable.” Backed by a 60 day moneyback guarantee, ChillWell 2.0 is also designed to be more portable than any other cooler on the market. The cooler has a rechargeable battery, allowing it to be used away from an immediate power source. Simply plug in ChillWell 2.0 via USB-C to charge it, then use the portable carrying handle to take it anywhere it needs to go. ChillWell 2.0 has scored top marks from industry experts for its ability to rapidly cool any space. Instead of waiting for a whole home HVAC system to kick into action, customers can start to feel cool air within minutes. “Insta-Frost uses an innovative, evaporation-based system with cooling cartridges to rapidly cool the air. Within minutes of turning it on, it starts to blow cool air across the room. We also encourage customers to add ice cubes to the water container, or place the included cooling cartridge in the freezer, for optimal cooling power.” Other unique features of ChillWell 2.0 include the multi-colored LED night lights, charging light indicators, and convenient carrying handle. ChillWell 2.0 is about more than helping customers stay cool all summer; it’s also about helping customers save money on home cooling and utility bills: “We’ve heard reports of customers reducing summer utility bills by $500 or more by using ChillWell 2.0 regularly. Instead of paying to cool an entire home, our customers can cool a specific room or space – all without permanently installing an AC system or running hoses through a window.” Customers who buy multiple ChillWell 2.0 portable coolers online today can save even more. ChillWell has dropped the price as low as $67.50 per cooler when ordering four coolers as part of the summer 2023 promotion. About ChillWell: ChillWell, found online at ChillWellShop.com, is a portable cooler company best-known for its flagship lineup of portable coolers. The company recently launched ChillWell 2.0 at a 55% discount for a limited time. The new and improved portable cooler features a rechargeable battery, convenient handle, and Insta-Frost technology for maximum cooling power. For more information, visit ChillWellShop.com. ### Contact Details Melissa Isabel +1 530-418-8423

May 24, 2023 01:35 PM Eastern Daylight Time

Article thumbnail News Release

Survey Reveals What the UK Audience Thinks of the Eurovision Voting System

Intelligiants Ltd

The yearlong anticipation and build-up for the 2023 Eurovision Song Contest ended with disappointment for the UK audience with Mae Muller’s placement in the competition. A recent survey by PartyCasino does however indicate that the support for Mae Muller’s performance and “I Wrote a Song” stands strong, after the Grand Final. Muller was recognized as one of the most talented artists among the finalists, alongside Finish artist Käärijä, with the song “Cha Cha Cha”. Käärijä, which finished second in the competition was on forehand a top candidate to be crowned winner of Eurovision 2023 and did in fact win the public votes, only to be beaten by Sweden’s Loreen, who took home the victory with the majority of the jury votes. When asked about their thoughts on the voting system in the Eurovision Grand Final, 45.20% of participants felt that the current system is working well, and 38.70% expressed the need for a simpler voting system. Additionally, the survey revealed that 37.50% of participants preferred only public votes per country, while 27.10% favoured a combination of jury and public votes from participating countries. Opinions on the frequency of the contest left the participants divided: Would the Eurovision Song Contest be more exciting if it was held every second year? 41.10% of the participants felt that the contest should not be held every second year. While 31.50% were unsure, and 27.40% were in favour of the contest taking place every second year and believed that it would make the event more exciting. The full survey and results can be found here. Contact Details Intelligiants Ltd F Kvarnebrink +27 71 221 8445 fred@intelligiants.net

May 24, 2023 11:30 AM Eastern Daylight Time

Image
Article thumbnail News Release

Intus Care Announces Data Partnership with North Carolina PACE Association

Intus Care

Intus Care, a pioneer in advanced software and data-driven solutions for geriatric healthcare, announced today its collaboration with the North Carolina PACE Association. NC PACE advocates for PACE (Programs of All-Inclusive Care for the Elderly) and strives to broaden its reach and success across the state. Intus Care contributes an innovative blend of automated software and Integrated Care Services (ICS) to this partnership. Already partnering with the majority of North Carolina PACE programs, Intus Care will now automate all benchmark reporting for partnered programs, while assuming responsibility for submissions from non-partnered programs. Utilizing this data, the Intus Care team will collaborate with the NC PACE Association to develop benchmarking reports, conduct data analysis, and present insights to the Association and its members. “We are pleased for this opportunity to work with such an innovative Association as they consistently find creative ways to empower their membership and facilitate the model’s success throughout the state,” said Intus Care Chief Strategy Officer Laura Ferrara. The NC PACE Association will collaborate with Intus Care's team of PACE specialists, led by Laura, to structure benchmarking reporting procedures and analyze data at the organizational, state, and national levels. Through quarterly presentations to the NC PACE Association and its members, Laura and the ICS team will showcase the benchmarking analysis, pinpoint areas of achievement and potential, and propose best practice interventions to empower performance. “The NC PACE Association, along with our NC PACE organizations, believes that reliable data leads to informed decisions. This, in turn, assists us with our mission: providing integrated managed care for the elderly and expanding PACE services statewide,” said Liz Bradsher, Executive Director of the NC PACE Association. "Intus Care shares our mission and we are eager to see the impact of this relationship within our NC PACE organizations, as well as within the state.” About Intus Care Intus Care empowers PACE organizations nationwide through automated software and PACE expert consulting. Our PACE-focused analytics platform improves clinical decision making and data accessibility, while our Integrated Care Service experts collaborate with programs to improve Compliance, Quality, Utilization, and more through a hands-on, data-driven approach. Intus Care currently works with over 40 PACE programs across 16 states and closed a $14.1M Series A in Q4 of 2022. Visit our website to learn more and to sign up for our newsletter intuscare.com. Contact Details SVM Public Relations Jordan Bouclin and Alison Matthiessen +1 401-490-9700 intuscare@svmpr.com Company Website https://www.intuscare.com/

May 24, 2023 10:00 AM Eastern Daylight Time

Article thumbnail News Release

BioNTech's mRNA Vaccine Shows Early Potential Against Pancreatic Cancer

MarketJar

One of the most stubborn, deadly cancers is pancreatic cancer. What if individualized mRNA vaccinations could support the immune system's defense? One of the deadliest forms of cancer around, pancreatic cancer is estimated to kill 88% of patients. It’s also one of the most recurrent cancers, with roughly 90% of patients experiencing a relapse within seven to nine months after surgery. Fortunately, a recent study of an mRNA vaccine for pancreatic cancer patients has provided a glimpse of hope. Scientists at Memorial Sloan Kettering (MSK) Cancer Center in New York just published the results of a small study that the group conducted in partnership with Germany’s BioNTech on pancreatic cancer patients over several years. The study used a pancreatic cancer mRNA vaccine tailored to each patient’s tumor to potentially help provoke an immune response. What’s revolutionary about the vaccines is that the German scientists tailored them to the mutated proteins on the surface of cancer cells instead of a mix of tumor and normal cells, which has been the method tried for decades. The cells were extracted from patients’ tumors by researchers at Memorial Sloan and sent to BioNTech, the company that created the highly-effective COVID-19 vaccine alongside Pfizer. Among the participants in the study, half of the patients’ immune systems learned how to recognize and fight off the cancer cells and showed no signs of relapse during the 18 months they were tracked. While promising, personalized mRNA cancer vaccines are still in their infancy and are too costly to be broadly used. Right now, regular cancer screening remains the best method for detecting cancers, however there are currently no screening tests for pancreatic cancer. Fortunately, that could soon change thanks to Mainz Biomed (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer Developing Early Screening Tests for Colon and Pancreatic Cancers On May 10, Mainz Biomed announced a partnership with Microba Life Sciences for the creation of PancAlert in addition to early colon cancer diagnostics. The technical characteristics of a novel pancreatic cancer screening test with DNA and microbiota indications should be enhanced. As part of the agreement, the two companies will conduct a pilot research project utilizing Microba’s proprietary metagenomic sequencing technology and bioinformatic tools in an effort to discover novel microbiome biomarkers to detect pancreatic cancer. The project, which is expected to run until late 2023, will use Microba's Community Profiler (MCP), a proprietary metagenomic platform technology that has proven to be a best-in-class research tool that can produce comprehensive and accurate species profiles of gastrointestinal samples. Mainz Biomed (NASDAQ:MYNZ) is also focused on commercializing its flagship product ColoAlert, a highly efficacious and simple-to-use detection test for colorectal cancer (CRC) that is already available in select international territories. In Q1 2023, the company also launched a corporate health program in Germany by integrating into BGM, a well-established corporate health program that provides services to employees at 48 of the 50 largest companies in Germany. On May 24, Mainz Biomed announced initial results from its colorectal cancer screening campaign with Zöller-Kipper GmbH through its BGM partnership. In April 2023, Zöller-Kipper selected ColoAlert for its corporate health program, which includes over 2,500 employees. According to the results, employees found the online patient portal easy-to-use and convenient and were able to readily access the portal, request a kit and securely receive results within five days. In order to process the ColoAlert PCR test kit, Mainz Biomed has added Eurofins GeLaMed to its network of lab partners. Eurofins GeLaMed is a division of the global laboratory company Eurofins Scientific, which conducts 450 million tests annually and has over 61,000 employees in 61 nations. Germany is home to four of its locations. Advancing Towards FDA Approval to Bring ColoAlert to the US Market Over the last few months, Mainz Biomed has continued to prepare for patient enrollment in its pivotal clinical trial for ColoAlert after successfully completing its pre-submission process with the FDA. ColoAlert will be examined in the FDA-registered trial "ReconAAsense" in order to obtain commercial approval in the United States. The company's business objective is to create scalable distribution across the nation once it receives approval through a cooperative partner program with regional and national laboratory service providers. Learn more about Mainz Biomed (NASDAQ:MYNZ) and its activities by clicking on this link. Disclaimer 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, Mainz Biomed NV. Market Jar Media Inc. has or expects to receive from Mainz Biomed NV’s Digital Marketing Agency of Record (Native Ads Inc.) eighty nine thousand seven hundred sixty four USD for 12 days (9 business days). 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on pressreach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on pressreach.com. 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Mainz Biomed NV’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Mainz Biomed NV’s industry; (b) market opportunity; (c) Mainz Biomed NV’s business plans and strategies; (d) services that Mainz Biomed NV intends to offer; (e) Mainz Biomed NV’s milestone projections and targets; (f) Mainz Biomed NV’s expectations regarding receipt of approval for regulatory applications; (g) Mainz Biomed NV’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Mainz Biomed NV’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Mainz Biomed NV’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Mainz Biomed NV’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Mainz Biomed NV’s ability to enter into contractual arrangements with additional Pharmacies; (e) the accuracy of budgeted costs and expenditures; (f) Mainz Biomed NV’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Mainz Biomed NV to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Mainz Biomed NV’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Mainz Biomed NV’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Mainz Biomed NV’s business operations (e) Mainz Biomed NV may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, Mainz Biomed NV undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Mainz Biomed NV nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Mainz Biomed NV nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Mainz Biomed NV or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Mainz Biomed NV or such entities and are not necessarily indicative of future performance of Mainz Biomed NV or such entities. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

May 24, 2023 09:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

OYO Launches Discounted Stays as Memorial Day Weekend Bookings Soar

OYO

Global travel technology company OYO has announced a special offer for the upcoming Memorial Day holiday. This Memorial Day weekend is expected to be the busiest since 2000. Due to record anticipated travelers for the weekend, OYO is offering discounted stays to help travelers plan their holidays within their budget. Travelers can avail 33% off on all stays from 27 th to 31 st May 2023. With this 33% off discount offer, travelers can book 2 nights and get 1 night stay for free at select OYO hotels across the US. To redeem the offer, customers need to book their stay on the OYO app or website and enter the promo code “MEMORIALDAY.” Customers can also book by calling our representatives on +1 405-342-7056. OYO is also seeing increased demand in cities like Atlanta, Houston, San Antonio & Jackson. Speaking about the upcoming season, Gautam Swaroop, CEO OYO International said, “Memorial Day is an important holiday for the Americans. We are preparing for the busy summer season across the states, which officially kicks off this weekend. We anticipate a surge in bookings, as reports suggest that 42.3 million Americans will be traveling 50 miles or more for the long weekend, an increase of 2.7 million compared to 2022. We expect record-breaking hotel bookings within city limits and along highways, as a vast majority of Americans, approximately 37.1 million travelers, will be hitting the road.” OYO offers hotels access to a large base of regular customers through its app and website, and lists hotels on multiple Online Travel Agents (OTAs) to boost booking demand and revenue. OYO’s best-in-class Artificial Intelligence-enabled pricing software automatically drives the best booking prices across all channels, based on room type, seasonality and other factors, therefore, enabling such an increase in online revenues. OYO has started offering hotels the flexibility of not having to invest heavily in redoing the hotel to join the OYO platform, something that other budget hotel chains insist on. Therefore, the initial investment to join OYO is minimal. It has been focusing instead on standardizing service led components such as customer support and booking experience. The company helps ensure great experience for customers, with ease of search and a quick booking experience, highly competitive room prices as per market demand patterns, automated tools such as Artificial Intelligence powered chatbots to quickly resolve customer queries, loyalty programs and easy refund, if needed. Earlier this year OYO said that it is planning to add over 100 hotels in the US in 2023. This is nearly double the number of hotels the company added to its portfolio in 2022. OYO will focus on adding more hotels in the states of Oregon, Washington, Texas, Oklahoma, Georgia and Florida. Texas continues to be the largest and fastest growing market for OYO in the US, while it also has sizable concentration of hotels in Oregon, South and North Carolina, Florida & Georgia. In 2022, the company saw a ~23% increase in new hotels added to its portfolio in the US vs 2021. Furthermore, OYO’s US operations have outpaced the budget hotel segment in terms of revenue per available room (RevPar) with an 18% rise in RevPar in 2022 vs pre-covid year, 2019. In contrast the budget hotel segment grew by only 6% in the US. The company also achieved a 48% growth in revenue from bookings on its own platform, such as the app, website, mobile web and call centers in Q4 2022 vs same period in 2021. OYO’s app saw highest growth with a 99% surge in revenue from bookings in Q4 2022 vs same period in 2021. The company had earlier disclosed that its app is the second most downloaded travel app with over 100 million downloads globally. About OYO: OYO is a global platform that aims to empower entrepreneurs and small businesses with hotels and homes by providing full-stack technology products and services that aim to increase revenue and ease operations; bringing easy-to-book, affordable, and trusted accommodation to customers around the world. OYO offers 40+ integrated products and solutions to patrons who operate over 168,711 hotel and home storefronts in more than 35 countries including India, Europe and Southeast Asia, as of September 30, 2022. For more information, visit www.oyorooms.com. Disclaimer: Oravel Stays Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its equity shares (the “Equity Shares”) and has filed the Draft Red Herring Prospectus (“DRHP”) with the Securities and Exchange Board of India (“SEBI”). The DRHP is available on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges, i.e., BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com, respectively, and is available on the websites of the Global Coordinators and Book Running Lead Managers, i.e., Kotak Mahindra Capital Company Limited, J.P. Morgan India Private Limited and Citigroup Global Markets India Private Limited at www.investmentbank.kotak.com, www.jpmipl.com and www.online.citibank.co.in/rhtm/citigroupglobalscreen1.htm; the websites of the Book Running Lead Managers, i.e., ICICI Securities Limited, Nomura Financial Advisory and Securities (India) Private Limited, JM Financial Limited and Deutsche Equities India Private Limited at www.icicisecurities.com, www.nomuraholdings.com/company/group/asia/india/index.html, www.jmfl.com and www.db.com/India, respectively. Investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, refer to the Red Herring Prospectus which may be filed with the Registrar of Companies in the future, including the section titled “Risk Factors”. Potential investors should not rely on the DRHP filed with SEBI for making any investment decision. The Equity Shares offered in the Fresh Issue (as defined in the DRHP) and the Offer for Sale (as defined in the DRHP) have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and, may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. Accordingly, the Equity Shares are only being offered and sold (i) within the United States only to “qualified institutional buyers” (as defined in Rule 144A under the Securities Act) in transactions exempt from, or not subject to, the registration requirements under the Securities Act, and (ii) outside the United States in offshore transactions in reliance on Regulation S under the Securities Act and pursuant to the applicable laws of the jurisdictions where those offers and sales are made. There will be no public offering of the Equity Shares in the United States. Contact Details Anupriya +91 97911 63065 anupriya.d@oyorooms.com Company Website https://www.oyorooms.com/

May 23, 2023 11:00 AM Eastern Daylight Time

Article thumbnail News Release

Emergent Health and Apollo Biowellness Announce Strategic Collaboration

Emergent Health Corp.

Emergent Health Corp. (OTC: EMGE), a curator, developer, and marketer of products in the Regenerative Health Space announced today that it will be collaborating with Apollo Biowellness, Inc., the entity that Boustead has engaged to conduct an IPO of the roll up of the regenerative medicine space, previously announced by Emergent on May 18, 2023. Apollo is an aggregate of manufacturing, distribution and marketing of regenerative products and brands in the regenerative space. This partnership, along with the previously announced spin-off of PharmaZu will continue to build significant value to Emergent. As part of the roll-up being conducted by Boustead and Apollo Biowellness, effective June 1, 2023, Mr. Morrison will take over as President/CEO of Apollo Biowellness. Mr. Morrison will remain as a member of the Board of Directors of the Emergent and will assume the Title of Chairman of the Board. He will continue to be intimately involved with Emergent and the continued development, marketing and distribution of its products and brands, The two companies will coordinate marketing strategies, manufacturing and work together to expand the products and brands. Jim Morrison stated, “Since taking the helm of Emergent, I have enjoyed the process of creating the Company’s vibrant products and brands in the regenerative biologic space. The opportunity to coordinate between Emergent and Apollo and expand the value of these products and brands as President of Apollo Biowellness is an exciting opportunity and will bring expanded value to Emergent. I look forward to continuing to be involved in the dynamic offerings of Emergent going forward.” Jim Zimbler, a member of the Board of Directors, and previously the President of the Company, has been re-appointed as Interim President of the Company, also effective June 1, 2023. In addition to bringing on new senior management, the Company will be announcing a new CFO and a will conduct a new executive search for a new permanent full time CEO to work with the current management and Board and team and Mr. Morrison and the Apollo Biowellness team. The Company will announce more Management updates shortly. Jim Zimbler stated, “Jim Morrison has done a magnificent job during his tenure as President, and I know he will be a tremendous asset to Apollo Biowellness. I look forward to a close continued relationship with Mr. Morrison and leaning on him for his sizable experience and tutelage related to products and brands. That will greatly enhance the value Emergent will receive from the sale of Evolutionary Biologics and the other entities.” ABOUT EMERGENT HEALTH CORPORATION Emergent curates, develops and sells products in the Regenerative Health Space. Its products comprise of ingestibles as well as topicals for the whole family. The company distributes its products online and through Content Based Shopping using Influencers to position products in their produced content throughout the United States and Internationally. Its subsidiaries; PharmaZu, is a pure play, e-commerce products and service provider focused on the Pet Community, Pet Pharmacy and Pet Wellness using Influencers and their content, including the pet pharmacy, vet telehealth and pet wellness businesses. Evolutionary Biologics, is a new kind of biologics company founded for a clear purpose: bring cutting edge regenerative products to the medical community. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure or prevent any disease. For more information, please visit Emergent's Website and Social Media on Twitter. Before using any products, you should always consult with your Veterinarian and/or Family Doctor. SAFE HARBOR STATEMENT This press release contains forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. FOR MORE INFORMATION, PLEASE CONTACT: Jim Morrison, Chairman of the Board James W. Zimbler – Interim President/Interim CEO Emergent Health Corporation Website i nfo@emergenthealthcompany.com Contact Details Emergent Health Corp. info@emergenthealthcompany.com Company Website https://emergenthealthcompany.com/

May 23, 2023 09:00 AM Eastern Daylight Time

Article thumbnail News Release

The Humane Society of the United States Addresses the Pet Poverty Crisis

YourUpdateTV

Most people are aware of how poverty and structural inequality create challenges and barriers to accessing healthy food, education, jobs, health care and housing and how inflation is only making the crisis worse. Pet resources are no different. Many families are struggling to afford and access veterinary care, food and supplies for their beloved pets. More than 20 million pets live in poverty - three times as many pets live in poverty as enter shelters every year. This is a long overlooked national crisis exacerbated by inflation and the economy. Recently, Kitty Block, President and CEO of the Humane Society of the United States, participated in a nationwide satellite media tour to discuss the launch of the More Than a Pet campaign and how the organization is addressing the crisis. A video accompanying this announcement is available at: https://youtu.be/GdaZXktSjNI Over the past 20 years, the Humane Society of the United States has helped half a million pets and their families by providing veterinary care and supplies at no cost, keeping families and pets together in over 50 communities across the U.S. Without these services, families are often forced to make choices about sacrificing their own needs, even food and medications for themselves, to prioritize care for their pet. No family should ever have to make that choice. Since 2002, the Humane Society of United States’ Pets for Life and Rural Area Veterinary Services programs have been helping pet owners across the U.S. by providing food, supplies and services for their cats and dogs at no cost. It is critical to close the gap that exists for people and pets in underserved areas. With the new campaign called “More Than a Pet,” the HSUS is sounding an alarm about this crisis that is only getting worse. The Humane Society of the United States is offering these tips for people to support their communities: Advocate for keeping pets and their people together by signing the HSUS petition to close the pet equity gap. Your voice can make a big impact for all animals. Volunteer with the Humane Society of the United States’ Pets for Life and Rural Area Veterinary Services programs, which increase access to pet care for underserved communities. Donate pet food to your local shelter or pet food pantry. If you know of a neighbor in need, offer to help drive them to a veterinary appointment, foster their pet temporarily or provide a bag of their pet’s favorite food to help close the access to pet care gap. The HSUS is inviting the public to show their support for this campaign by sharing why their animal companion is #MoreThanAPet to them, at humanesociety.org/morethanapet. Campaign partner Smalls is donating a bowl of food for every photo shared, up to $1M, to pets and their families in need. Learn More and Get Involved About Kitty Block Kitty Block is the chief executive officer and president of the Humane Society of the United States and also chief executive officer of Humane Society International. She leads the nation's most effective animal protection organization in the fight for all animals. Block was named president and CEO of the Humane Society of the United States in January 2019, becoming the first woman to hold the position in the organization’s history. Block first joined the HSUS as a legal investigator in 1992 and was instrumental in bringing cruelties such as horse slaughter and the killing of dogs and cats for their fur in China to light. She led the HSUS’s efforts to secure protections for dolphins with successful litigation and landmark dolphin-safe tuna legislation. In addition, she was one of the architects of a successful lawsuit over commercial whaling brought against Japan by Australia in the International Court of Justice. She has served as an adviser to the White House on trade and the environment, and she has served multiple elected terms on the International Dolphin Conservation Agreement International Review Panel, which works with governments on monitoring violations of the agreement. Block received a law degree from The George Washington University in 1990 and a bachelor’s degree in communications and philosophy from the University of New Hampshire in 1986. She is a lifelong animal lover who helped her mother rescue and care for pets and other animals in need as a child. Block lives in Washington, D.C., with her husband and daughter, their street dog rescue, Lilly, and rescue cats, Misti and Storm Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

May 22, 2023 10:15 AM Eastern Daylight Time

Video
Article thumbnail News Release

From Jam Session to Record Contract: Meet “BANDED”, America’s Newest Music Competition Series

YourUpdateTV

Are you ready to discover the next big music super band? “BANDED” is a first-of-its-kind music competition series that takes you behind the scenes of the music industry and lets you witness the birth of the next big music band. Recently, Brandon Jenner, Host of “BANDED”, and Mark Schulman, “BANDED” Judge conducted a satellite media tour to talk about the show. A video accompanying this announcement is available at: https://youtu.be/JqTjH3jvu10 AXS TV —a subsidiary of Anthem Sports & Entertainment, Inc. —puts the spotlight on rising stars from across the country in the all-new original music competition BANDED, an innovative series that redefines the traditional “build-a-band” concept and showcases exceptional up-and-coming artists who can play, write, and sing. BANDED episodes will premiere every Saturday at 9 p.m. ET. on AXS TV. The series also will roll out weekly across all AXS TV digital channels. BANDED is hosted by musician and television personality Brandon Jenner, with recording artist and American Idol finalist Didi Benami as co-host. In the series premiere, 25 contenders were placed into five brand new multi-genre bands under the tutelage of GRAMMY®-winning and -nominated songwriters, producers, and artists such as Songwriters Hall of Fame honoree Wendy Starland, credited with discovering and developing Lady Gaga; as well as Paul Ebersold, Steve Diamond, Justin Wilson, and Dave Pahanish. Each week will feature a roster of legendary mentors and guest judges from across the music spectrum, such as Metal icons Vince Neil and Kip Winger; chart-topping Country star Steve Azar; Vans Warped Tour mastermind Kevin Lyman; and world-class rock ‘n roll drummer Mark Schulman, among many others. The inaugural season presents eight all-new episodes, with six hour-long episodes bookended by the 90-minute season premiere and season finale. A special video podcast will accompany each episode, as BANDED contestants, and stars breakdown all the latest happenings from the show. “We are extremely pleased to announce our partnership with AXS TV in launching the inaugural season of BANDED,” said Nico Albano, Executive Producer of the series. “AXS TV’s national and digital platforms are incredibly robust, giving viewers multiple ways to conveniently enjoy our content. We hope that this will be the beginning of a long-lasting relationship between AXS TV and BANDED, and we look forward to continuing to work with them as we move forward into the future.” “ BANDED is the perfect complement to our growing lineup of all-new original music-themed programming, putting a fresh spin on the standard music competition format that brings viewers into the fascinating creative process that each band undertakes,” said Katie Daryl, AXS TV’s Vice President of Programming. “We have some truly talented competitors and world-class mentors onboard, and we cannot wait to share all of this and more with our audience when BANDED premieres on AXS TV’s platforms next month.” GameTV will be the exclusive Canadian broadcaster of BANDED. The series will air every Saturday at 7 p.m. ET on GameTV, beginning July 8. “We are excited to be the exclusive home in Canada, and look forward to premiering it this summer,” said Maria Donatelli, Director of Programming for GameTV. Series sponsors include Embassy Suites by Hilton Nashville Downtown, Verijet, Colgate Optic White, Maggiano’s Little Italy, Bulova/Citizen, PRS Guitars, Roland, Gretsch, Zildjian, DW, Fender, and Remo. For more information, please visit www.BANDEDtv.com. Show Teaser About BANDED BANDED, produced by Shadow Entertainment Group, is the first music reality competition show that focuses on the musical talents of the contestants. It aims to give viewers an inside look into the real artistry of creating music. Leveraging highly successful mentors and judges, BANDED will take viewers behind the scenes to witness magic in the making. For more information about the show visit www.BANDEDtv.com About AXS TV AXS TV is a leading multi-platform music and entertainment digital platform and television company owned and operated by Anthem Sports & Entertainment, Inc. AXS TV’s broad library offers content headlined by concerts and music-inspired programming, world-class professional wrestling and MMA. AXS TV’s signature programs include The Top Ten Revealed, The Very VERY Best of the 80s, and Parking Lot Payday. The channel also is the home of IMPACT Wrestling, New Japan Pro-Wrestling and Invicta Fighting Championships. AXS TV is available nationally in the United States, and parts of Canada and the Caribbean. Additionally, AXS TV’s digital programming can be enjoyed on several different platforms including the AXS.TV website and the Network’s app AXS TV NOW, and FAST Channel, as well as on the Network’s official YouTube channel, Facebook and Instagram pages, Twitter and TikTok profiles. For a full list of providers and territories, please visit axs.tv/subscribe. About GameTV GameTV is Canada’s leading destination for game shows and entertainment, powered by a rich programming lineup that boasts both classic and modern game shows as well as a wide selection of reality-based series, back-to-back nightly movies, documentaries and more. Game TV is the home of the most recognizable game shows and is the exclusive broadcaster of the UK produced series The Masked Dancer and The Masked Singer. GameTV is available nationally on Bell, Cogeco, Telus, Rogers, Shaw and Videotron, among others. For more information about the network, visit www.gametvnetwork.com. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

May 19, 2023 02:10 PM Eastern Daylight Time

Video
Article thumbnail News Release

UAT Group Reached Agreement with Strategic Capital Partner

Umbra Applied Technologies Group, Inc.

Umbra Applied Technologies Group, Inc. (OTC: UATG) announced today that it has reached an agreement with a strategic capital partner to support the growth of its subsidiary Ossifix Orthopedics. The private equity firm specializes in the medical field. The firm’s focus provides strategic growth capital and works with existing management to increase sales, benefiting both its own investors and value for all Ossifix shareholders. As part of the agreement, the new partner will become a nine percent stakeholder in Ossifix Orthopedics and will provide up to $2 million in funding capital. The firm will also provide additional value such as its investors and relationships to include an extensive portfolio of surgeons, medical facilities and knowledgebase, which will be utilized to further expand marketing and sales for Ossifix. Chief Financial Officer, Thomas Crom stated, “Although this reduces our ownership in Ossifix it dramatically increases Ossifx capability to move forward without any dilution to UATG’s shareholders. This Ossix transaction illustrates the creative ways UATG can fund its subsidiaries without diluting its current UATG shareholders. This type of funding is complex and time-consuming but illustrates Ossifix’s intrinsic value is now being recognized by others.”. This announcement on Friday came amid growing optimism among the Company’s executives that the traction the UAT Group conglomerate has gained in the first half of the year will exceed its expectations for the year; positioning it for a remarkable year. The investment into Ossifix contributes to the Company's consolidated growth initiatives which include augmenting existing product offerings and service capabilities of its subsidiaries as well as positioning infrastructure resources in support of planned expansion. UAT Group Chairman, Alex Umbra commented, “As always, UAT Group stands ready to support each of our subsidiaries, in any way necessary, as we capitalize on the values we create together. This new relationship will not only provide strategic capital but will continue to support growth objectives that will bolster shareholder value, streamline balance sheet debt and enable verticals to be realized sooner”. About Umbra Applied Technologies Group, Inc. The firm is located in Tampa, Florida and focuses on advanced technologies across many disciplines. UAT Group is a holding company with interests in both public and private companies during the early stages of development as well as growth stages of companies with a synergistic business model to UAT Group subsidiaries. For more information, visit: www.uatgroup.com Investor and Media Contact: info@uatgroup.com For more information about Ossifix Technologies, go here: https://ossifixtech.com/ NEITHER THE SECURITIES EXCHANGE COMMISSION NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE. Forward-Looking Information This news release may include "forward-looking statements" including forecasts, estimates, expectations, and objectives for future operations including but not limited to its ability to conclude a business combination with a third party, sale of assets, return of capital or initial public offering and a secondary listing on the OTC as a result of aforementioned and its ability to fund the exploration of its assets through the raising of equity or debt capital or through funding by a joint venture partner that are subject to a number of assumptions, risks, and uncertainties, many of which are beyond the control of Umbra Applied Technologies Group including but not limited to capital markets and securities risks and continued development success on technology. There can be and are no actual or implied guarantees that any of the above activities will be completed or completed on terms acceptable to the Company and its shareholders or approved by any regulatory authority having jurisdiction. Such forward-looking information represents management's best judgment based on information currently available. No forward-looking statement can be guaranteed, and actual future results may vary materially. Umbra Applied Technologies Group does not assume the obligation to update any forward-looking statement, except as required by applicable law. Contact Details Umbra Applied Technologies Group, Inc. info@uatgroup.com

May 19, 2023 08:00 AM Eastern Daylight Time

1 23456 ... 208